InDex Pharmaceuticals Q4 2022: Phase lll prospects at a discount - Redeye

Redeye leaves its comments on InDex following the company’s Q4 report. We adjust our forecasts according to the delay of CONCLUDE and additional capital need, which lowers our valuation. At yesterday’s closing price, the market values InDex below its net cash position, which is remarkable.

Länk till analysen i sin helhet: https://www.redeye.se/research/884211/index-pharmaceuticals-valuation-below-cash-position-is-unjustified?utm_source=finwire&utm_medium=RSS